BACKGROUND: The cytokine-deficiency-induced colitis susceptibility (Cdcs)1 locus is a major modifier of murine inflammatory bowel disease (IBD) and was originally identified in experimental crosses of interleukin-10-deficient (Il10(-/-)) mice. Congenic mice, in which this locus was reciprocally transferred between IBD-susceptible C3H/HeJBir-Il10(-/-) and resistant C57BL/6J-Il10(-/-) mice, revealed that this locus likely acts by inducing innate hypo- and adaptive hyperresponsiveness, associated with impaired NF-kappaB responses of macrophages. The aim of the present study was to dissect the complexity of Cdcs1 by further development and characterization of reciprocal Cdcs1 congenic strains and to identify potential candidate genes in the congenic interval. METHODS: In total, 15 reciprocal congenic strains were generated from Il10(-/-) mice of either C3H/HeJBir or C57BL/6J genetic backgrounds by 10 cycles of backcrossing. Colitis activity was monitored by histological grading. Candidate genes were identified by fine mapping of congenic intervals, sequencing, microarray analysis, and a high-throughput real-time reverse-transcription polymerase chain reaction (RT-PCR) approach using bone marrow-derived macrophages. RESULTS: Within the originally identified Cdcs1-interval, 3 independent regions were detected that likely contain susceptibility-determining genetic factors (Cdcs1.1, Cdcs1.2, and Cdcs1.3). Combining results of candidate gene approaches revealed Fcgr1, Cnn3, Larp7, and Alpk1 as highly attractive candidate genes with polymorphisms in coding or regulatory regions and expression differences between susceptible and resistant mouse strains. CONCLUSIONS: Subcongenic analysis of the major susceptibility locus Cdcs1 on mouse chromosome 3 revealed a complex genetic structure. Candidate gene approaches revealed attractive genes within the identified regions.
BACKGROUND: The cytokine-deficiency-induced colitis susceptibility (Cdcs)1 locus is a major modifier of murineinflammatory bowel disease (IBD) and was originally identified in experimental crosses of interleukin-10-deficient (Il10(-/-)) mice. Congenic mice, in which this locus was reciprocally transferred between IBD-susceptible C3H/HeJBir-Il10(-/-) and resistant C57BL/6J-Il10(-/-) mice, revealed that this locus likely acts by inducing innate hypo- and adaptive hyperresponsiveness, associated with impaired NF-kappaB responses of macrophages. The aim of the present study was to dissect the complexity of Cdcs1 by further development and characterization of reciprocal Cdcs1 congenic strains and to identify potential candidate genes in the congenic interval. METHODS: In total, 15 reciprocal congenic strains were generated from Il10(-/-) mice of either C3H/HeJBir or C57BL/6J genetic backgrounds by 10 cycles of backcrossing. Colitis activity was monitored by histological grading. Candidate genes were identified by fine mapping of congenic intervals, sequencing, microarray analysis, and a high-throughput real-time reverse-transcription polymerase chain reaction (RT-PCR) approach using bone marrow-derived macrophages. RESULTS: Within the originally identified Cdcs1-interval, 3 independent regions were detected that likely contain susceptibility-determining genetic factors (Cdcs1.1, Cdcs1.2, and Cdcs1.3). Combining results of candidate gene approaches revealed Fcgr1, Cnn3, Larp7, and Alpk1 as highly attractive candidate genes with polymorphisms in coding or regulatory regions and expression differences between susceptible and resistant mouse strains. CONCLUSIONS: Subcongenic analysis of the major susceptibility locus Cdcs1 on mouse chromosome 3 revealed a complex genetic structure. Candidate gene approaches revealed attractive genes within the identified regions.
Authors: Wendy S Garrett; Graham M Lord; Shivesh Punit; Geanncarlo Lugo-Villarino; Sarkis K Mazmanian; Susumu Ito; Jonathan N Glickman; Laurie H Glimcher Journal: Cell Date: 2007-10-05 Impact factor: 41.582
Authors: Maike F de Buhr; Michael Mähler; Robert Geffers; Wiebke Hansen; Astrid M Westendorf; Jörg Lauber; Jan Buer; Brigitte Schlegelberger; Hans J Hedrich; Andre Bleich Journal: Physiol Genomics Date: 2006-05-16 Impact factor: 3.107
Authors: Max Brenner; Hsiang-Chi Meng; Nuriza C Yarlett; Bina Joe; Marie M Griffiths; Elaine F Remmers; Ronald L Wilder; Pércio S Gulko Journal: J Immunol Date: 2005-06-15 Impact factor: 5.422
Authors: David E Nowak; Bing Tian; Mohammad Jamaluddin; Istvan Boldogh; Leoncio A Vergara; Sanjeev Choudhary; Allan R Brasier Journal: Mol Cell Biol Date: 2008-03-24 Impact factor: 4.272
Authors: Arianna Nenci; Christoph Becker; Andy Wullaert; Ralph Gareus; Geert van Loo; Silvio Danese; Marion Huth; Alexei Nikolaev; Clemens Neufert; Blair Madison; Deborah Gumucio; Markus F Neurath; Manolis Pasparakis Journal: Nature Date: 2007-03-14 Impact factor: 49.962
Authors: R Steven Esworthy; Byung-Wook Kim; Garrett P Larson; M L Richard Yip; David D Smith; Min Li; Fong-Fong Chu Journal: Inflamm Bowel Dis Date: 2010-09-24 Impact factor: 5.325
Authors: Andrew E Hillhouse; Matthew H Myles; Jeremy F Taylor; Elizabeth C Bryda; Craig L Franklin Journal: Mamm Genome Date: 2011-06-30 Impact factor: 2.957
Authors: Partha Mukhopadhyay; Guy Brock; Cynthia Webb; M Michele Pisano; Robert M Greene Journal: Birth Defects Res A Clin Mol Teratol Date: 2012-02-28
Authors: Joerg Ermann; Wendy S Garrett; Juhi Kuchroo; Khadija Rourida; Jonathan N Glickman; Andre Bleich; Laurie H Glimcher Journal: Proc Natl Acad Sci U S A Date: 2011-04-11 Impact factor: 11.205
Authors: G Jurisic; J P Sundberg; A Bleich; E H Leiter; K W Broman; G Buechler; L Alley; D Vestweber; M Detmar Journal: Genes Immun Date: 2010-03-11 Impact factor: 2.676
Authors: Scott E Levison; Paul Fisher; Jenny Hankinson; Leo Zeef; Steve Eyre; William E Ollier; John T McLaughlin; Andy Brass; Richard K Grencis; Joanne L Pennock Journal: BMC Genomics Date: 2013-02-26 Impact factor: 3.969